United Kingdom Oral Anti-Diabetes Drugs Market Insight
United Kingdom Oral Anti-Diabetes Drugs Market is growing at an 2.8% CAGR, driven by type 2 diabetes
United Kingdom Oral Anti-Diabetes Drugs Market Insights Forecasts to 2035
- The United Kingdom Oral Anti-Diabetes Drugs Market Size Was Estimated at USD 1340.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 2.8% from 2025 to 2035
- The United Kingdom Oral Anti-Diabetes Drugs Market Size is Expected to Reach USD 1766.7 Million by 2035
Notable Insights for United Kingdom Oral Anti-Diabetes Drugs Market
- By drug class, metformin dominates with approximately 40–50% share due to first-line NHS recommendation for type 2 diabetes management
- SGLT2 inhibitors account for nearly 20–25% share, driven by cardiovascular and renal protective benefits
- DPP-4 inhibitors hold around 15–20% share due to favorable safety profile and once-daily dosing convenience
- Around 60–70% of UK type 2 diabetes patients are treated with oral anti-diabetic drugs as first-line or combination therapy.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Oral Anti-Diabetes Drugs Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Oral Anti-Diabetes Drugs Market
- Novo Nordisk
- AstraZeneca
- Merck & Co.
- Sanofi
- Boehringer Ingelheim
- Eli Lilly and Company
- Novartis
- Takeda Pharmaceutical Company
- Others
Recent Developments:
- In April 2025, Eli Lilly’s orforglipron, a once-daily oral GLP-1, achieved positive Phase 3 results, showing significant HbA1c reduction and weight loss, advancing as a potential non-injectable type 2 diabetes therapy.
- In September 2023, Mounjaro (tirzepatide) was recommended by NICE for type 2 diabetes in the UK, improving glycemic control and weight loss, often used alongside oral anti-diabetic therapies in practice.
Market Segmentation:
United Kingdom Oral Anti-Diabetes Drugs Market, By Drug Class
- Biguanides (Metformin)
- SGLT2 Inhibitors
- DPP-4 Inhibitors
- Sulfonylureas
- Others
United Kingdom Oral Anti-Diabetes Drugs Market, By Indication
- Type 2 Diabetes
- Type 1 Adjunct Therapy
- Prediabetes
United Kingdom Oral Anti-Diabetes Drugs Market, By End User
- Hospitals & Clinics
- Retail Pharmacies
- Homecare Settings
United Kingdom Oral Anti-Diabetes Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Specialty Pharmacies
- Online Channels
Expert Views:
The UK Oral Anti-Diabetes Drugs Market is expected to grow steadily due to rising diabetes prevalence, obesity burden, and strong NHS-led early diagnosis programs. Experts highlight that metformin will remain the cornerstone therapy, while SGLT2 inhibitors and combination oral therapies will drive future growth. Advancements in cardiometabolic-focused drugs and improved treatment adherence strategies are expected to enhance long-term disease management through 2035.